Focused on accelerating the path to precision health through Next Generation Dx and Tx, New Clinical Delivery Models and Operational Excellence. Investing in Health IT, Health Services, Diagnostics, Digital Therapeutics, Non-Invasive Medical Technologies and Biopharma Tools.

Font Icon Class: 
Primary Image: 
Where We Invest Image: 


Check-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.


Jiff's enterprise health benefits platform saves employers money by organizing all your vendors, curating the relevant ones for each employee, and incentivizing each employee to use the solutions that will create the most value.

The Daily Startup: Neuronetics Raises $34.3M for Device to Treat Depression

Neuronetics, which sells a noninvasive device to treat clinical depression by stimulating the brain, has raised a $34.3 million Series F round, Timothy Hay reports for Dow Jones VentureWire. Other medical-device companies offer devices that stimulate the brain in the hope of ameliorating depression, but they mostly are invasive, such as involving implanted devices, such as pulse generators.

Neuronetics Picks Up $34M for Device to Treat Depression

Neuronetics Inc., which has been selling a device to treat clinical depression by stimulating the brain, has raised a $34.3 million Series F round to keep up with demand since more health insurers have agreed to reimburse doctors for using the device to treat patients.

The company is also in the midst of studies that seek to show that its magnetic stimulation device is safe to treat adolescents, said Christopher Thatcher, Neuronetics' chief executive.

The funding was led by new investor GE Ventures, joined by most of the company's returning investors, he said.

Neuronetics, Inc.

Neuronetics, Inc., is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses.

New Veracyte/GE Partnership May Lead To Improved IPF Diagnosis

The molecular diagnostic company Veracyte, Inc. and the multinational conglomerate corporation GE have established a research partnership focused on developing novel solutions able to improve the diagnosis of diseases such as Idiopathic pulmonary fibrosis (IPF). The companies did not disclose the financial terms of the collaboration.


Caremerge forges meaningful connections between providers, payers, families and seniors seeking to improve communication in today’s complex healthcare environment.

Iora Health

Iora Health is restoring humanity to health care by providing a radically different model of primary care built from the ground up.


Subscribe to RSS - Healthcare